Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Diclectin, Delayed Release Tablets, in Healthy Volunteers

Pregnancy Related Clinical Trial

Official title:

Open Randomized Cross-over Two-period Study on Comparative Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Enteric-soluble Film-coated Tablets, 10 mg + 10 mg (Valenta Farm, Russia) in Healthy Volunteers in Fasted Conditions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05498233
• Other study ID #: DIP-05-01-2022
• Status: Completed
• Phase: N/A
• Start date: August 18, 2022
• Est. completion date: September 19, 2022

Study information

• Verified date: July 2023
• Source: Valenta Pharm JSC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aimed for:

1. Comparative assessment of pharmacokinetic parameters and bioequivalence of the drug Doxylamine + Pyridoxine, enteric-soluble film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSC, Russia), and Diclectin, delayed-release tablets, 10 mg + 10 mg (registrant: Tzamal Bio-Pharma, Israel, manufacturer: Duchesnay Inc, Canada), in healthy volunteers in fasted conditions.

2. Comparative evaluation of the safety of the drug Doxylamine + Pyridoxine, enteric-soluble film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSK, Russia), and Diclectin, delayed-release tablets, 10 mg + 10 mg (registrant: Tzamal Bio-Pharma, Israel, manufacturer: Duchesnay Inc, Canada), based on the analysis of adverse events (AEs).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: September 19, 2022
• Est. primary completion date: September 19, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

1. Voluntary and handwritten informed consent form signed by a healthy volunteer to participate in the study before any of the study procedures.

2. Women of reproductive age (18 to 49 years inclusive, according to World Health Organization criteria).

3. Verified diagnosis "healthy" (absence of abnormalities according to clinical, laboratory, instrumental methods of examination stipulated by the protocol).

4. Blood pressure (BP) level: systolic blood pressure (SBP) from 100 to 139 mmHg, diastolic blood pressure (DBP) from 60 to 89 mmHg (inclusive).

5. Heart rate (HR) from 60 to 90 bpm (inclusive).

6. Respiratory rate (HR) from 12 to 18 bpm (inclusive).

7. Body temperature of 36 to 36.9°C (inclusive).

8. Body mass index (BMI) is 18.5 = BMI = 30 kg/m2, and the body weight must be = 45 kg.

9. Consent to use adequate methods of contraception throughout the study and for 30 days after completion, negative pregnancy test.

10. Volunteers must behave adequately, coherent speech must be observed.

Exclusion Criteria:

1. A history of allergic reactions.

2. Drug intolerance of active and/or excipients included in the study drugs in the anamnesis.

3. Chronic diseases of the cardiovascular, lymphatic, respiratory, nervous, endocrine, digestive, musculoskeletal, covering, immune systems, as well as of the urogenital system and hematopoietic organs.

4. Values of standard laboratory and instrumental indices beyond the limits of local laboratory norms.

5. History of gastrointestinal surgery (except appendectomy at least 1 year before screening).

6. Diseases/conditions that the investigator believes may affect the absorption, distribution, metabolism, or excretion of the study medication.

7. Acute infectious disease less than 4 weeks prior to screening.

8. Taking drugs that have a significant effect on hemodynamics and drugs that affect liver function (barbiturates, benzodiazepines, omeprazole, cimetidine, etc.) for less than one month before screening.

9. Regular intake of drugs less than 2 weeks before screening and one-time intake of drugs less than 7 days before screening.

10. Donating blood or plasma less than 3 months before the screening visit.

11. Use of hormonal contraceptives less than 2 months before the screening visit.

12. Using depot injections of any medications less than 3 months prior to the screening visit.

13. Pregnancy or lactation, positive pregnancy test.

14. Participation in another clinical trial less than 3 months before screening or concurrently with this study.

15. Taking more than 10 units of alcohol (1 unit of alcohol is equivalent to 330 ml of beer, 150 ml of wine, or 40 ml of spirits) in the week in the last month before inclusion in the study or anamnestic evidence of alcoholism, drug abuse, or medicine abuse.

16. Smoking.

17. Positive blood tests for antibodies to human immunodeficiency virus (HIV) type 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus antigens, laboratory examination of biomaterial (nasopharyngeal swab) for SARS-Cov-2 RNA (COVID-19).

18. Clinically significant abnormalities on electrocardiogram (ECG).

19. Positive urinalysis for narcotics and powerful drugs.

20. Positive breath alcohol vapor test.

21. Scheduling an inpatient stay during the study period, for any reason other than hospitalization required by this protocol.

22. Failure or inability to comply with protocol requirements, perform protocol-prescribed procedures, diet, and activity regimen.

23. Observance of a religious fast or special diet (e.g., vegetarian, vegan).

24. Other conditions that, in the opinion of the Investigator, preclude a volunteer from enrolling in the study or may result in early withdrawal from the study, including special lifestyles (night work, extreme physical activity).

Withdrawal criteria:

1. The volunteer's refusal to further participate in the study.

2. Failure of the volunteer to comply with the rules of participation in the study (skipping study procedures, independent use of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.).

3. Occurrence of causes/occurrence during the study of situations that threaten the safety of the volunteer (e.g., hypersensitivity reactions, etc.).

4. Volunteers included in the study in violation of the inclusion/inclusion criteria.

5. Development of a severe and/or serious adverse event (AE) in a volunteer during the study.

6. Missing 2 or more consecutive blood samples or 3 or more blood samples during one Period of the pharmacokinetic portion of the study.

7. Occurrence of vomiting/diarrhea within 24 h of study drug administration (the choice of time interval is based on the tmax parameter value for doxylamine and pyridoxal-5-phosphate not exceeding 7.2 ± 1.9 and 11.7 ± 5.3 h, respectively, according to the manufacturer of the reference drug).

8. Positive urine test for narcotic substances and potent drugs.

9. Positive breath alcohol vapor test.

10. A positive pregnancy test.

11. Positive test for SARS-Cov-2 RNA (COVID-19);

12. Other causes occurring in the course of the study that prevent the study from being conducted according to the protocol.

Related Conditions & MeSH terms

• Nausea
• Pregnancy Related

Intervention

Drug:
• Doxylamine + Pyridoxine
A single dose of R or T drug in each of 2 periods of the study in fasted conditions

Locations

Country	Name	City	State
Russian Federation	Llc "Certa Clinic"	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Valenta Pharm JSC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics - Cmax (Doxylamine)	Maximum plasma concentration (Cmax)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - Cmax (Pyridoxal-5-phosphate)	Maximum plasma concentration (Cmax)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - tmax (Doxylamine)	Time to reach Cmax (tmax)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - tmax (Pyridoxal-5-phosphate)	Time to reach Cmax (tmax)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - AUC0-t (Doxylamine)	Area under the plasma concentration-time curve from time 0 to t (AUC0-t)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - AUC0-t (Pyridoxal-5-phosphate)	Area under the plasma concentration-time curve from time 0 to t (AUC0-t)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - AUC0-inf (Doxylamine)	Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - AUC0-inf (Pyridoxal-5-phosphate)	Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - AUCextr (Doxylamine)	Extrapolated AUC, defined as (AUC0-inf - AUC0-t)/AUC0-inf	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - AUCextr (Pyridoxal-5-phosphate)	Extrapolated AUC, defined as (AUC0-inf - AUC0-t)/AUC0-inf	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - t1/2 (Doxylamine)	Elimination half-life (t1/2)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - t1/2 (Pyridoxal-5-phosphate)	Elimination half-life (t1/2)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - kel (Doxylamine)	Elimination constant (kel)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - kel (Pyridoxal-5-phosphate)	Elimination constant (kel)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - MRT (Doxylamine)	Mean residence time (MRT)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Pharmacokinetics - MRT (Pyridoxal-5-phosphate)	Mean residence time (MRT)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Bioequivalence - ratio of Cmax (Doxylamine)	Ratio of geometric mean Cmax after intake of R or T (with 90% confidence intervals)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Bioequivalence - ratio of Cmax (Pyridoxal-5-phosphate)	Ratio of geometric mean Cmax after intake of R or T (with 90% confidence intervals)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Bioequivalence - ratio of AUC0-t (Doxylamine)	Ratio of geometric mean AUC0-t after intake of R or T (with 90% confidence intervals)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Bioequivalence - ratio of AUC0-t (Pyridoxal-5-phosphate)	Ratio of geometric mean AUC0-t after intake of R or T (with 90% confidence intervals)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Bioequivalence - ratio of AUC0-inf (Doxylamine)	Ratio of geometric mean AUC0-inf after intake of R or T (with 90% confidence intervals)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Primary	Bioequivalence - ratio of AUC0-inf (Pyridoxal-5-phosphate)	Ratio of geometric mean AUC0-inf after intake of R or T (with 90% confidence intervals)	From 0 to 72 hours (Day 1-4 and Day 22-25)
Secondary	Safety and Tolerability: adverse event (AE) number and frequency	Number and frequency of adverse events (AEs)	From the screening (and signing informed consent form) to Day 29 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	serious adverse event (SAE) number and frequency	Number and frequency of serious AEs (SAEs)	From the screening (and signing informed consent form) to Day 29 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: vital signs - systolic blood pressure (SBP)	SBP, mmHg	Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: vital signs - diastolic blood pressure (DBP)	DBP, mmHg	Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: vital signs - respiratory rate (RR)	RR, breaths per minute	Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: vital signs - heart rate (HR)	HR, beats per minute	Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: vital signs - body temperature	Body temperature, centigrade scale	Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: physical examination results	Physical examination will follow the general rules of internal medicine: general examination, examination of mucous membranes and skin, including palpation of lymph nodes, evaluation of the musculoskeletal system, palpation, percussion, and auscultation of the main organ systems (cardiovascular, respiratory, digestive, and urinary systems) will be performed sequentially.	Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: heart rate (beats per minute)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: PQ interval (ms)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QRS complex (ms)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QTc (ms)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis - color	Color of the urine	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis - transparency	Transparency of the urine	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis - pH	pH of the urine	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis - specific gravity	Specific gravity of the urine	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis - protein	Protein in the urine (g/L)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis - glucose	Glucose in the urine (mmol/L)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis (microscopy) - red blood cells	Red blood cells in the urine (number in sight)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis (microscopy) - white blood cells	White blood cells in the urine (number in sight)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis (microscopy) - epithelial cells	Epithelial cells in the urine (number in sight)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis (microscopy) - cylinders	Cylinders in the urine (number in sight)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis (microscopy) - mucus	Mucus in the urine (presence in sight)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: urinalysis (microscopy) - bacteria	Bacteria in the urine (number in sight)	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - hemoglobin	Hemoglobin, g/dL	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - red blood cells	Red blood cells, 10^6/uL	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - hematocrit	Hematocrit, %	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - platelets	Platelets, 10^3/uL	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - white blood cells	White blood cells, 10^3/uL	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - erythrocyte sedimentation rate	Erythrocyte sedimentation rate, mm per hour	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - neutrophils	Neutrophils, %	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - lymphocytes	Lymphocytes, %	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - eosinophils	Eosinophils, %	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - monocytes	Monocytes, %	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: complete blood count - basophils	Basophils, %	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: blood test results - total protein	Total protein in blood serum, g/L	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: blood test results - creatinine	Creatinine in blood serum, umol/L	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: blood test results - glucose	Glucose in blood serum, mmol/L	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: blood test results - total bilirubin	Total bilirubin in blood serum, umol/L	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: blood test results - total cholesterol	Total cholesterol in blood serum, mmol/L	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: blood test results - alanine transaminase (ALT)	ALT in blood serum, U/L	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: blood test results - aspartate transaminase (AST)	AST in blood serum, U/L	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Secondary	Safety and Tolerability: blood test results - alkaline phosphatase (ALP)	ALP in blood serum, U/L	Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)